{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+hydrochloride+%28HCl%29&page=14", "query": { "intervention": "Doxorubicin hydrochloride (HCl)", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 617, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+hydrochloride+%28HCl%29&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+hydrochloride+%28HCl%29&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T06:32:04.927Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00524459", "title": "Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "FEMALE", "summary": "Up to 64 Years · Female only" }, "enrollment_count": 6, "start_date": "2007-05", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524459" }, { "nct_id": "NCT02448537", "title": "A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Sarcoma" ], "interventions": [ { "name": "PM01183", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448537" }, { "nct_id": "NCT04739800", "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Mucinous Adenocarcinoma", "Recurrent Fallopian Tube Transitional Cell Carcinoma", "Recurrent Fallopian Tube Undifferentiated Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Seromucinous Carcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Ovarian Undifferentiated Carcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Undifferentiated Carcinoma", "Refractory Fallopian Tube Clear Cell Adenocarcinoma", "Refractory Fallopian Tube Endometrioid Adenocarcinoma", "Refractory Fallopian Tube High Grade Serous Adenocarcinoma", "Refractory Fallopian Tube Mucinous Adenocarcinoma", "Refractory Fallopian Tube Transitional Cell Carcinoma", "Refractory Fallopian Tube Undifferentiated Carcinoma", "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian Endometrioid Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Refractory Ovarian Low Grade Serous Adenocarcinoma", "Refractory Ovarian Mucinous Adenocarcinoma", "Refractory Ovarian Seromucinous Carcinoma", "Refractory Ovarian Transitional Cell Carcinoma", "Refractory Ovarian Undifferentiated Carcinoma", "Refractory Primary Peritoneal Clear Cell Adenocarcinoma", "Refractory Primary Peritoneal Endometrioid Adenocarcinoma", "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Transitional Cell Carcinoma", "Refractory Primary Peritoneal Undifferentiated Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2021-06-10", "completion_date": "2027-06-25", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 384, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739800" }, { "nct_id": "NCT04139304", "title": "A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Plasmablastic Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-05-24", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 8, "location_summary": "Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04139304" }, { "nct_id": "NCT00968253", "title": "RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "Everolimus (RAD001)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ara-C (Cytarabine)", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 24, "start_date": "2009-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00968253" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT03009201", "title": "Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Soft Tissue Sarcoma", "Locally Advanced Angiosarcoma", "Locally Advanced Leiomyosarcoma", "Locally Advanced Liposarcoma", "Locally Advanced Malignant Peripheral Nerve Sheath Tumor", "Locally Advanced Myxofibrosarcoma", "Locally Advanced Undifferentiated Pleomorphic Sarcoma", "Metastatic Angiosarcoma", "Metastatic Epithelioid Sarcoma", "Metastatic Fibrosarcoma", "Metastatic Liposarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Myxofibrosarcoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Pleomorphic Rhabdomyosarcoma", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Undifferentiated (Embryonal) Sarcoma", "Unresectable Leiomyosarcoma", "Unresectable Liposarcoma", "Unresectable Malignant Peripheral Nerve Sheath Tumor", "Unresectable Soft Tissue Sarcoma", "Unresectable Synovial Sarcoma", "Unresectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 16, "start_date": "2017-03-10", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03009201" }, { "nct_id": "NCT00012311", "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "CMF regimen", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "18 Years to 59 Years · Female only" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012311" }, { "nct_id": "NCT06829199", "title": "A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Triple Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin (hydrochloride)", "type": "DRUG" }, { "name": "Boserolimab", "type": "BIOLOGICAL" }, { "name": "Epirubicin Hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib (if approved/available locally)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-03-26", "completion_date": "2031-03-18", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06829199" }, { "nct_id": "NCT02112916", "title": "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult T Acute Lymphoblastic Leukemia", "Ann Arbor Stage II Adult Lymphoblastic Lymphoma", "Ann Arbor Stage II Childhood Lymphoblastic Lymphoma", "Ann Arbor Stage III Adult Lymphoblastic Lymphoma", "Ann Arbor Stage III Childhood Lymphoblastic Lymphoma", "Ann Arbor Stage IV Adult Lymphoblastic Lymphoma", "Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma", "Childhood T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 847, "start_date": "2014-10-04", "completion_date": "2026-09-16", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T06:32:04.927Z", "location_count": 188, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112916" } ] }